198 related articles for article (PubMed ID: 7013437)
21. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
Hortobagyi GN; Yap HY; Wiseman CL; Blumenschein GR; Buzdar AU; Legha SS; Gutterman JU; Hersh EM; Bodey GP
Cancer Treat Rep; 1980 Jan; 64(1):157-9. PubMed ID: 6991103
[TBL] [Abstract][Full Text] [Related]
22. [Advanced carcinoma of the breast. Results of a polychemotherapeutic protocol].
Fazio M; Manca A; Rodino A; Cavallero P; Tripodina A
Minerva Ginecol; 1982 Sep; 34(9):667-70. PubMed ID: 7145204
[No Abstract] [Full Text] [Related]
23. Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.
Miller AB; Klaassen DJ; Boyes DA; Dodds DJ; Gerulath A; Kirk ME; Levitt M; Pearson JG; Wall C
Can Med Assoc J; 1980 Sep; 123(5):365-71. PubMed ID: 7020903
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant chemotherapy for osteosarcoma at the Singapore General Hospital.
Khor TH; Chua EJ; Tan BC; Chia KB
Singapore Med J; 1983 Apr; 24(2):95-8. PubMed ID: 6577611
[No Abstract] [Full Text] [Related]
25. [Combination chemotherapy in metastatic breast cancer].
Kuten A; Lev L; Mohaliver J; Robinson E
Harefuah; 1981 Feb; 100(3):118-20. PubMed ID: 7262675
[TBL] [Abstract][Full Text] [Related]
26. Moderately high-dosage methotrexate medication in metastatic breast cancer.
Wils JA
Neth J Med; 1980; 23(2):59-61. PubMed ID: 7374869
[No Abstract] [Full Text] [Related]
27. The relation between sex hormone binding globulin and response to cytotoxic chemotherapy (CAF therapy) in breast cancer.
Murayama Y; Nagashima M; Aoyagi K; Asano K
Nihon Gan Chiryo Gakkai Shi; 1980 Jun; 15(3):334-8. PubMed ID: 7190994
[No Abstract] [Full Text] [Related]
28. Preliminary report of a clinical trial of the treatment of patients with advanced stage III and IV ovarian cancer with melphalan, 5-fluorouracil, and methotrexate in combination and sequentially: a study of the Clinical Trials Group of the National Cancer Institute of Canada.
Klaassen DJ; Boyes DA; Gerulath A; Levitt M; Miller AB; Pearson JG
Cancer Treat Rep; 1979 Feb; 63(2):289-95. PubMed ID: 376135
[No Abstract] [Full Text] [Related]
29. Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer. An EORTC trial.
Heuson JC; Sylvester R; Engelsman E
Eur J Cancer (1965); 1980; Suppl 1():113-7. PubMed ID: 7032920
[No Abstract] [Full Text] [Related]
30. [Adjuvant chemotherapy of primary breast cancer].
Heuson JC; Mattheiem WH
Acta Chir Belg; 1977; 76(4):437-43. PubMed ID: 919991
[No Abstract] [Full Text] [Related]
31. Adjuvant chemotherapy for breast cancer.
Holland JF
Surg Clin North Am; 1981 Dec; 61(6):1361-70. PubMed ID: 6797078
[No Abstract] [Full Text] [Related]
32. [A study on the treatment of pulmonary metastatic osteosarcoma].
Yamawaki S; Isu K; Ubayama Y; Nakasato T; Goto M; Ishii S; Sasaki T; Usui M; Yagi T
Gan To Kagaku Ryoho; 1982 Jul; 9(6):998-1005. PubMed ID: 6964046
[TBL] [Abstract][Full Text] [Related]
33. [Effect of antiblastic polychemotherapy (CMF) on the number of circulating monocytes in patients with breast cancer].
Bariani L; Dolcetti U; Indelli M; Gualandi G; Malacarne P; Castaldi G
Minerva Med; 1982 Oct; 73(39):2641-8. PubMed ID: 7121879
[TBL] [Abstract][Full Text] [Related]
34. [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
Sauter C
Schweiz Med Wochenschr; 1994 Oct; 124(43):1879-81. PubMed ID: 7973513
[No Abstract] [Full Text] [Related]
35. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
[TBL] [Abstract][Full Text] [Related]
36. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
[TBL] [Abstract][Full Text] [Related]
37. The current status of systemic adjuvant therapy in the management of primary breast cancer.
Fisher B; Wolmark N
Surg Clin North Am; 1981 Dec; 61(6):1347-60. PubMed ID: 7031938
[No Abstract] [Full Text] [Related]
38. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
39. [CMF or CAF combination chemotherapy for breast cancer].
Ota J
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1886-90. PubMed ID: 8978791
[TBL] [Abstract][Full Text] [Related]
40. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
Panasci LC
J Clin Oncol; 2006 May; 24(15):2392; author reply 2392. PubMed ID: 16710042
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
